- Home
- CMDB vs VNDA Comparison
CMDB vs VNDA Comparison
Compare CMDB & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMDB
- VNDA
- Stock Information
- Founded
- CMDB 2023
- VNDA 2002
- Country
- CMDB Monaco
- VNDA United States
- Employees
- CMDB N/A
- VNDA N/A
- Industry
- CMDB
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- CMDB
- VNDA Health Care
- Exchange
- CMDB Nasdaq
- VNDA Nasdaq
- Market Cap
- CMDB 291.4M
- VNDA 249.4M
- IPO Year
- CMDB N/A
- VNDA 2006
- Fundamental
- Price
- CMDB $14.60
- VNDA $5.33
- Analyst Decision
- CMDB
- VNDA Strong Buy
- Analyst Count
- CMDB 0
- VNDA 2
- Target Price
- CMDB N/A
- VNDA $16.50
- AVG Volume (30 Days)
- CMDB 84.5K
- VNDA 495.7K
- Earning Date
- CMDB 11-12-2025
- VNDA 11-05-2025
- Dividend Yield
- CMDB N/A
- VNDA N/A
- EPS Growth
- CMDB N/A
- VNDA N/A
- EPS
- CMDB N/A
- VNDA N/A
- Revenue
- CMDB $799,159,000.00
- VNDA $203,467,000.00
- Revenue This Year
- CMDB N/A
- VNDA $15.45
- Revenue Next Year
- CMDB N/A
- VNDA $37.82
- P/E Ratio
- CMDB N/A
- VNDA N/A
- Revenue Growth
- CMDB 152.53
- VNDA 11.78
- 52 Week Low
- CMDB $8.46
- VNDA $3.81
- 52 Week High
- CMDB $14.97
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- CMDB N/A
- VNDA 66.70
- Support Level
- CMDB N/A
- VNDA $4.84
- Resistance Level
- CMDB N/A
- VNDA $5.48
- Average True Range (ATR)
- CMDB 0.00
- VNDA 0.21
- MACD
- CMDB 0.00
- VNDA 0.07
- Stochastic Oscillator
- CMDB 0.00
- VNDA 86.57
About CMDB Costamare Bulkers Holdings Limited Common Stock
Costamare Bulkers Holdings Ltd is an international owner and operator of dry bulk vessels providing multinational transportation of dry bulk commodities for a broad range of customers. Its owned fleet consists of 38 vessels, with a total carrying capacity of approximately 3,017,000 dwt. The company's vessels transport a broad range of bulks across the shipping routes around the world. Iron ore, coal and grain constitute the majority of its cargoes.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.